|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
WO2017060201A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Immatics Biotechnologies Gmbh |
Anti-wt1/hla-specific antibodies
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
US11505599B2
(en)
|
2016-01-14 |
2022-11-22 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for Foxp3-derived peptides
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
WO2018200582A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
|
WO2019006464A1
(en)
|
2017-06-30 |
2019-01-03 |
Memorial Sloan Kettering Cancer Center |
COMPOSITIONS AND METHODS OF ADOPTIVE CELLULAR THERAPY AGAINST CANCER
|
|
JP7072792B2
(ja)
*
|
2017-12-11 |
2022-05-23 |
国立大学法人神戸大学 |
二重特異性抗体
|
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CN112041432A
(zh)
|
2018-02-15 |
2020-12-04 |
纪念斯隆-凯特林癌症中心 |
Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
CN112512538A
(zh)
*
|
2018-05-18 |
2021-03-16 |
国家儿童医疗中心 |
改进的靶向t细胞疗法
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EP4126044A4
(en)
*
|
2020-04-02 |
2024-09-04 |
The Board Of Regents Of The University Of Texas System |
CD5L-BINDING ANTIBODIES AND USES THEREOF
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
IL300543A
(en)
*
|
2020-09-24 |
2023-04-01 |
Hoffmann La Roche |
Prevention or reduction of adverse effects associated with a bispecific T-cell antibody
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
JP2025513714A
(ja)
*
|
2022-03-22 |
2025-04-30 |
モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｃｄ３に特異的な脱免疫抗体
|